Lofexidine a centrally acting alpha-2
adrenergic agonist, was launched specifically
for symptomatic relief in patients undergoing
opiate withdrawal programmes. In open studies in small groups of methadone
dependent patients, lofexidine treatment enabled successful detoxification (defined as remaining drug free for
10 days after the last methadone
dose) in greater than 65% of patients.
No comments:
Post a Comment